This tip is from Corey Nahman's Internet Drug News (one of the most widely read pharma news indexes and an important news source for PharmaGossip):
Poor Sepracor. On Friday they posted a second-quarter profit, reversing a year-earlier loss, but cut its forecast for the year saying sales of its sleeping pill Lunesta will be lower than expected.
The Marlborough, Massachusetts-based drug company said on a conference call that the rate of growth in the sleep drug market has been hurt by concerns over claims that certain drugs can cause episodes of amnesia, sleep walking and binge eating.
As a result, Sepracor said it is lowering its forecast for 2006 Lunesta sales to $620 million from a previous forecast of $650 million, and it cut its 2006 earnings per share forecast to $1.13 a share from a previous forecast of $1.50 a share.
Its revenue outlook fell to $1.175 billion from $1.275 billion.
"The market has really changed over the past six months," said David Southwell, Sepracor's chief financial officer, in an interview.
Could this mean sweet dreams for Rozerem?
Cheer up Dave, you'll do OK when Sepracor is bought by, say, Pfizer.
Hat tip: Corey (pic)
3 comments:
Like I said in your other post about Rozerem, their mechanism of action is entirely different. Rozerem isn't a sedative in the strict sense of the word, like Lunesta, Ambien, Restoril, and the others. In fact, many people who start taking Rozerem are able to stop taking it once their sleep-wake cycles are fixed.
As such I don't really see the correlation between problems for Lunesta affecting Rozerem sales...
Indeed. Rozerem sales may actually do better.
Hence my "sweet dreams" comment. Meaning a better outcome for them than the nightmare for the others.
I now realise that I had used "sweet dreams" one way and you have taken the meaning another way! :-0
Cheers.
Jack
Ah, I thought you might have meant that after I posted it, but blogger doesn't allow you to edit comments. ;_;
Cheers!
Post a Comment